Natixis’s Immuneering IMRX Stock Holding History

Natixis’s Portfolio IMRX Stock Details IMRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-380	Closed	-$2K	–	1263
2026 Q1	$2K	Buy	+380	New	+$1.95K	﹤0.01%	1055

Other funds holding IMRX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

DCF Advisers Greenwich, Connecticut $566M AUM 197.74% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Natixis's IMRX Position: Q2 2026 in Review

Natixis sold out of Immuneering (IMRX) in Q2 2026, closing a stake of 380 shares — an estimated $2K sold.

Natixis first reported a position in IMRX in Q1 2026 and held it in 1 quarter. The position peaked at $2K in Q1 2026. 111 funds tracked by Wall St. Rank hold IMRX as of Q2 2026.

Natixis reported no remaining Immuneering position as of Q2 2026 after selling out during the quarter.
Natixis sold 380 Immuneering shares in Q2 2026, an estimated $2K.
Natixis first reported a position in Immuneering in Q1 2026 and held it in 1 quarter.
Natixis's Immuneering position peaked at $2K in Q1 2026.
111 funds tracked by Wall St. Rank held Immuneering as of Q2 2026.

Based on Natixis's 13F filing for Q2 2026, filed 13 Aug 2026.